WILSON, Wyoming, Aug. 24, 2017 /PRNewswire/ -- SynAgile Corporation (www.SynAgile.com), a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse™ technology platform, today announced the closing of a $10.4 million round of equity investment. The round was led by affiliates of TAMCAP LLC. The proceeds will be used to conduct the first-in-human, Phase 2 clinical trial of SynAgile's DopaFuse™ delivery system. The DopaFuse™ delivery system is the first non-invasive, continuous, levodopa-carbidopa delivery system for the treatment of motor fluctuations associated with Parkinson's disease.
SynAgile is a biopharmaceutical company focused on developing and commercializing transformative therapeutics using its proprietary OraFuse™ noninvasive, continuous, oral dosing technology, with an initial focus on treating debilitating motor complications in patients with Parkinson's disease using its DopaFuse™ levodopa-carbidopa delivery system.
OraFuse and DopaFuse are trademarks of SynAgile Corporation.
Ephraim Heller, (510) 788-4435
SOURCE SynAgile Corporation